Customer Support Specialist 2 - Sun, Thurs 1:30PM, 10:00PM
About the job
- A High School Diploma or General Education Degree (GED).
- Three or more years of customer service experience.
- Three or more years of experience in a sales or customer service environment focused on delivering exceptional customer experience.
- Strong verbal and written communication, problem-solving, organizational, and interpersonal skills, with the ability to work effectively across teams and adapt to changing priorities.
- Ability to work independently, maintain schedule adherence, and use a computer and telephone simultaneously in a customer support environment.
- Must be 18 years of age or older.
- Authorization to work in the United States without sponsorship.
- Manage inbound and outbound customer contacts, including phone calls, voicemail, and email inquiries from providers, sales teams, and other internal customers.
- Investigate and resolve questions, service issues, and customer complaints; identify and escalate high-priority concerns when appropriate.
- Maintain current knowledge of sales policies, organizational structure, territory assignments, and sales initiatives while documenting new procedures and opportunities for improvement.
- Deliver accurate, professional service while meeting attendance and schedule expectations, completing required training and assessments, and complying with Quality Management System policies and company standards.
- Experience working in an inbound/outbound contact center within the healthcare industry.
- Experience supporting healthcare providers, inside sales teams, or other internal business partners in a high-volume customer service environment.
About the company
Abbott develops and sells medical technologies and health solutions across cardiovascular care, diabetes management, diagnostics, nutrition, and neuromodulation. Cardiovascular devices help manage heart health; diabetes products enable glucose monitoring; diagnostic tests provide timely results; nutrition products support health; neuromodulation therapies target the nervous system to relieve pain or aid movement. It differentiates itself with a broad, integrated portfolio and a focus on accessibility and affordability of technologies worldwide. Its goal is to improve global health and well-being by delivering life-changing technologies that are accessible and affordable.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Get referred to Abbott
See people who can refer or advise you
Simplify's Take
What believers are saying
- Medicare covers SimpleScreen CRC for eligible patients, lowering adoption friction immediately.
- Abbott's March 23, 2026 Exact Sciences deal adds oncology diagnostics growth.
- Berry Street and Google Health widen Lingo's distribution and engagement in 2026.
What critics are saying
- September 14, 2026 DOJ settlement cost Abbott $384,999,040 and exposed manufacturing failures.
- Abbott still faces NEC litigation after the August 2026 $670 million settlement.
- A second infant-formula crisis would destroy Abbott's Nutrition franchise and invite federal procurement bans.
What makes Abbott unique
- Exact Sciences gives Abbott Cologuard, Oncotype DX, and Cancerguard across cancer screening.
- SimpleScreen CRC, launched September 30, 2026, expands Abbott's blood-and-stool colorectal screening portfolio.
- Lingo plus Google Health and Berry Street turns glucose data into consumer coaching.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Professional Development Budget
Wellness Program
Growth & Insights and Company News
6 month growth
↑ 7%1 year growth
↑ 7%2 year growth
↑ 17%Abbott has launched SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test for adults aged 45 and older at average risk. Developed by Freenome and exclusively commercialised by Abbott, the test joins Cologuard Plus in Abbott's screening portfolio. The test was validated in PREEMPT CRC, involving over 48,000 adults. It demonstrated 81.1% overall sensitivity for colorectal cancer and 90.4% specificity for advanced colorectal neoplasia, correctly detecting about eight in 10 colorectal cancers. SimpleScreen CRC is covered by Medicare with no out-of-pocket costs for eligible Medicare Part B patients. The American Cancer Society recommends blood-based screening for individuals who decline or do not complete preferred stool-based or visual screening tests. Abbott provides patient support including blood-draw coordination, insurance assistance, and screening reminders.
Ga. woman sues over spinal cord stimulator failure. * kyla asbury * sep 28, 2026 Updated 2 hrs ago. ST. LOUIS - A Georgia woman has filed a federal lawsuit against Abbott Laboratories alleging that an implanted spinal cord stimulator failed to provide the promised treatment for chronic pain, caused painful electrical shocks and other complications, and ultimately required surgical removal. Toni Ford filed the compaint September 18 in U.S. District Court for the Eastern District of Missouri. The case alleges product liability and administrative law claims against Abbott Laboratories involving a Proclaim XR5 spinal cord stimulation system. According to the complaint, Ford is a Georgia resident, while Abbott is an Illinois corporation with its principal place of business in Lake County, Ill. The lawsuit states that the court has jurisdiction because the parties are citizens of different states and the amount in controversy exceeds $75,000. Ford alleges she was surgically implanted with the Abbott Proclaim XR5 spinal cord stimulator on or about Sept. 15, 2023, after first undergoing a temporary external trial of an SCS system. The complaint says Abbott sales representatives identified as Kelly and Kyle, whose last names were not provided, told Ford the permanent device would provide long-term pain relief, was safe and supported by clinical validation, would be functionally equivalent to the trial system and would reduce her need for other chronic-pain treatment. Ford alleges she relied on those representations when deciding to proceed with permanent implantation. The complaint alleges the implanted system failed shortly after surgery. Ford says she underwent another surgical procedure on Sept. 22, 2023, to remove the SCS system because of mechanical and therapeutic failure, including loss of therapeutic effectiveness and severe shocking. She alleges she continues to experience pain and symptoms associated with the malfunctioning system. The complaint further alleges she suffered physical injury, worsening pain, emotional distress, medical expenses and diminished quality of life. A central allegation in the lawsuit concerns the regulatory history of the spinal cord stimulator. The complaint states that the device was originally approved by the Food and Drug Administration in 2001 under PMA P010032 for Advanced Neuromodulation Systems, which was later acquired by St. Jude Medical and ultimately became part of Abbott's SCS portfolio following Abbott's 2017 acquisition of St. Jude Medical. Ford alleges that the original system was substantially changed over time through more than 230, and in other portions of the complaint nearly 250, PMA supplements involving firmware, waveform architecture, battery design, wireless communication, user interfaces and other components. The complaint alleges those cumulative changes materially altered the device's safety and performance without a new PMA or new clinical testing of the final marketed system. It identifies numerous supplements and regulatory actions dating from 2009 through 2024, including changes involving the Proclaim XR5, Proclaim XR5 Mini, Proclaim IPG family and Proclaim SCS family. The filing alleges the changes affected the device's stimulation effects, safety controls, battery stability and susceptibility to failure. Ford's complaint also points to recalls involving Abbott's Proclaim-series devices. It alleges that on Sept. 11, 2023, the FDA classified five recalls of Proclaim-series spinal cord stimulation devices as Class I recalls. The complaint says those recalls followed reports of painful electrical shocks, sudden device shutdowns and failures to provide therapeutic stimulation. It further alleges that Abbott initiated a recall of the Proclaim 5 Elite SCS pulse generator on May 16, 2024, because of a product-labeling defect. The lawsuit alleges that the Proclaim XR5 implanted in Ford incorporated features that were not part of the original 2001 device, including firmware-dependent controls, Bluetooth-based smartphone programming and burst and high-frequency stimulation patterns. Ford alleges she was not told that the device differed materially from the original system or that it had undergone the changes described in the complaint. The filing also alleges that Abbott did not adequately disclose risks involving stimulation failure, lead migration, charging errors, nerve damage and device failure. The complaint asserts eight causes of action against Abbott, including strict products liability based on an alleged manufacturing defect, failure to warn, negligence per se based on alleged federal regulatory violations, breach of express warranty, breach of implied warranty of merchantability and fitness for a particular purpose, negligence, negligent misrepresentation and fraudulent concealment. Ford alleges Abbott failed to comply with various federal requirements involving device changes, adverse-event reporting, design validation, manufacturing-process validation, complaint investigations, corrective and preventive actions and labeling updates. Ford also alleges Abbott represented that its spinal cord stimulation systems were safe and effective for long-term treatment of chronic pain, had been adequately tested, were FDA-approved and clinically validated, and provided reliable therapy and wireless programming. The complaint alleges those representations were misleading because the Proclaim XR5 had not been clinically validated in its final marketed form and because of the changes and adverse events described in the filing. The fraudulent-concealment claim alleges Abbott had access to adverse-event reports and internal product complaint information and failed to disclose information concerning alleged design and firmware changes, therapy interruptions, device shutdowns during charging and unintended stimulation. Ford alleges those issues were associated with recalls, including the Class I recalls described in the complaint. Ford is seeking compensatory damages to be determined at trial for physical injuries, pain and suffering, emotional distress, medical expenses, loss of enjoyment of life and other damages. She is represented by Adam M. Evans of the Carlson Law Firm. U.S. District Court for the Eastern District of Missouri case number: 1:26-cv-00213 More news. * Updated 2 hrs ago ST. LOUIS - A Georgia woman has filed a federal lawsuit against Abbott Laboratories alleging that an implanted spinal cord stimulator failed t...
Abbott's Ahmed Fahmy on regulatory harmonisation and expanding access to medicines in Africa. As regulatory cooperation continues to advance across Africa, greater alignment between markets could play an important role in creating more efficient and predictable pathways for medicines to reach patients. Ahead of AfriSummit 2026, PharmaReg AfriSummit spoke with Ahmed Fahmy, Head of Africa Region for Established Pharmaceuticals at Abbott, about the opportunity presented by regulatory harmonisation, the role of biosimilars in broadening access, and how stronger collaboration between regulators and industry can support Africa's evolving healthcare needs. Ahmed Fahmy is Head of Africa Region for Established Pharmaceuticals at Abbott. He brings more than 25 years of pharmaceutical industry experience, including 15 years in senior leadership roles across Abbott, Eli Lilly, Pfizer and Novartis. His expertise spans general management, P&L leadership, market access, commercial excellence and healthcare partnerships across diverse African and Middle Eastern markets. Ahmed is passionate about expanding patient access to high-quality medicines, strengthening local capabilities and advancing sustainable healthcare growth across Africa. Share one key priority, development or opportunity your organization sees within Africa's regulatory and healthcare landscape. Briefly explain how your organisation is contributing to progress in this area. One key priority/opportunity for Abbott's medicines business in Africa is leveraging regulatory harmonization to expand access to affordable, high-quality medicines. In May 2026, WHO and the African Medicines Agency (AMA) formalized their cooperation to advance regulatory convergence and reduce duplication across the continent. The continued operationalization of the AMA is creating important momentum toward greater regulatory harmonization, strengthened reliance mechanisms, and consistent standards for the quality, safety, and efficacy of medicines across African markets. For Abbott, this evolution aligns closely with its commitment to expanding access to high-quality medicines and addressing evolving healthcare needs across Africa and emerging markets. PharmaReg AfriSummit see greater regulatory alignment and collaboration as important enablers of more efficient, predictable pathways for bringing innovative and affordable medicines to patients. Abbott is committed to contributing constructively to this dialogue and to working alongside regulators and other stakeholders to support the development of stronger, more aligned regulatory frameworks in Africa. In particular, biosimilars can play an important role in broadening access to essential treatments, including in oncology, women's health, and immunology, by leveraging Abbott's growing biosimilar portfolio and supporting the evolution of Africa's regulatory ecosystem. Share what you are looking forward to at AfriSummit 2026. Highlight the perspective, expertise or value you hope to bring to the discussions. At AfriSummit 2026, Abbott looks forward to engaging with regulators, policymakers, healthcare leaders and industry stakeholders to advance a more collaborative, efficient and sustainable regulatory environment across Africa. Abbott aims to contribute its experience and perspectives on strengthening regulatory harmonization by reducing duplication and promoting greater alignment of registration requirements across African markets, while identifying opportunities to improve regulatory efficiency and accelerate patient access to innovative and established medicines. The Summit will also provide an important platform to explore partnerships that strengthen local capabilities, enhance healthcare system resilience and address country-specific health priorities. Abbott is committed to partnering with health authorities, industry stakeholders, and the broader healthcare community to advance regulatory excellence and help ensure that more patients across Africa can access high-quality medicines. For Abbott, progress will depend on continued collaboration, strengthening regulatory alignment while responding to the distinct healthcare priorities and realities of individual African markets. As Ahmed Fahmy highlights, AfriSummit 2026 provides an opportunity to bring regulators, policymakers, healthcare leaders and industry together around practical areas of progress, from reducing duplication and improving regulatory efficiency to strengthening local capabilities and expanding access to high-quality medicines.
Abbott and Berry Street partner to expand personalized nutrition support for consumers seeking better metabolic health. * Partnership combines Abbott's Lingo continuous glucose monitor with Berry Street's insurance-covered registered dietitian support, helping consumers translate glucose insights into healthier behaviors * Research shows registered dietitian-led medical nutrition therapy can improve glucose control and cardiometabolic health outcomes, highlighting the power of combining glucose data plus human expertise[1] ABBOTT PARK, Ill. and NEW YORK, Sept. 23, 2026 /PRNewswire/ - Abbott (NYSE: ABT) and Berry Street today announced an exclusive partnership to help people take a more proactive approach to nutrition and long-term health. The partnership brings together Lingo, Abbott's consumer biowearable that provides personal glucose insights, with live nutrition coaching from Berry Street, one of the nation's largest insurance-covered nutrition care platforms, helping consumers turn metabolic insights into meaningful action. Lingo is an over-the-counter continuous glucose monitor (CGM) for individuals 18 years of age or older who are not using insulin and want to make informed decisions about their health. By showing how food, movement and stress affect glucose, Lingo can help people make small, science-backed adjustments that can lead to measurable improvements in overall health and well-being. Through the partnership, Berry Street* and Lingo users can now: * Access registered dietitians specially trained on Lingo and continuous glucose monitors * Receive personalized nutrition recommendations informed by their glucose trends * Meet virtually through convenient one-to-one appointments Metabolic health challenges continue to affect millions of Americans. According to the Centers for Disease Control and Prevention, more than 115 million US adults have prediabetes, yet approximately 80% are unaware they have it.[2] Left unaddressed, prediabetes can increase the risk of developing Type 2 diabetes, heart disease and stroke. "At Abbott, we believe the future of health lies in giving people the tools and support they need to understand their bodies and take action," said Olivier Ropars, divisional vice president of Abbott's Lingo business. "By partnering with Berry Street, we're combining the advanced biosensing technology of Lingo with expert nutrition guidance to help people make informed nutrition and lifestyle decisions that can support healthy habits over time." Published research from the American Journal of Clinical Nutrition has shown that registered dietitian-led nutrition therapy can improve glucose control, weight management, cholesterol levels and other cardiometabolic markers, including among people with prediabetes.[3] [4] "For too long, nutrition guidance has relied on broad recommendations that may not reflect how an individual's body actually responds to food," said Noah Kotlove, chief executive officer and co-founder of Berry Street. "The combination of continuous glucose insights and registered dietitian expertise creates a more personalized approach to nutrition. Together with Lingo, we're helping consumers move beyond guesswork and build sustainable habits rooted in a deeper understanding of their health." The partnership with Berry Street builds on Abbott's commitment to helping people improve their health through science-backed nutrition innovation. Lingo adds to that legacy by providing personal metabolic insights that help consumers make more informed nutrition and lifestyle decisions. * Berry Street nutrition services are in-network with more than 1,250 health plans, with 96% of people paying no out-of-pocket costs. Coverage depends on the specific details of an individual's insurance plan. Frequently Asked Questions What is Lingo? Lingo is Abbott's over-the-counter continuous glucose monitoring (CGM) system designed for individuals 18 years and older who are not using insulin. Lingo provides ongoing glucose insights, helping people understand how food, exercise, sleep and stress affect their glucose levels and metabolic health. By turning real-time glucose data into personalized insights, Lingo is designed to help people make informed lifestyle choices in support of their personal wellness goals. What will this partnership bring to Lingo and Berry Street users? The partnership will combine Abbott's Lingo glucose insights with Berry Street's registered dietitians trained on Lingo, who will interpret glucose data into personalized nutrition plans tailored to an individual's health goals. How can a Lingo user access the Berry Street nutritionists and how much will it cost? A Lingo user will be directed to sign up for Berry Street nutritionist services on the Lingo website and from email communications directly from Lingo. Berry Street appointments are virtual, making them accessible wherever you are in the US. Berry Street also accepts coverage from more than 1,250 health plans, so 96% of clients pay $0 out-of-pocket. Coverage depends on the specific details of an individual's insurance plan. How can a Berry Street user access their glucose data and how much will it cost? For the first time and through this exclusive partnership, Berry Street users can now obtain Lingo at a discounted price, enabling them to gain a better understanding of how their behavior and lifestyle changes can affect their glucose. By seeing how their glucose is reacting to food, exercise, sleep and stress, Berry Street users can make continuous and ongoing modifications as they work to address and improve their health concerns. Additionally, Berry Street dietitians can view their patient's glucose data providing additional personalized guidance and coaching. Berry Street users will receive a 15% discount on 4-week Lingo plans. Why is tracking glucose important for people who do not have diabetes? Glucose is the body's primary source of energy and plays a central role in overall metabolic health. Even in people without diabetes, glucose levels are influenced by everyday factors such as nutrition, physical activity, sleep and stress. By understanding glucose patterns, people can better assess how daily habits affect their bodies and make choices that support energy, well-being and long-term health. Tracking these patterns over time may also help identify risks for chronic conditions, including prediabetes, which affects more than 115 million U.S. adults. About Lingo The Lingo Glucose System is intended for users 18 years and older, not on insulin. It is not intended for diagnosis of diseases, including diabetes. The Lingo program does not guarantee that everyone will achieve the same results as individual responses may vary. Consult your healthcare professional before making changes to your diet or exercise regimen or if you have an eating disorder or a history of eating disorders. Lingo can be purchased at hellolingo.com, Amazon, Walmart (in-store and online), Walgreens, BestBuy.com and Publix. Lingo is available in the US and the UK. The Lingo app is now available for download for Android through the Google Play Store and for iOS on the Apple App Store. About Abbott Abbott is a global healthcare leader that helps people live more fully at all stages of life. Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Its 122,000 colleagues serve people in more than 160 countries. About Berry Street Berry Street is on a mission to transform how Americans eat through nutrition therapy. Berry Street's platform connects individuals needing evidence-based nutrition care with an expansive network of Registered Dietitians and AI-powered tools. From weight management, diabetes, and heart health to kidney disease, maternal health, and 30+ other conditions, Berry Street's clinical team delivers personalized nutrition interventions tailored to each patient's unique physiological and psychological needs, improving outcomes and reducing total cost of care. Berry Street works with some of the largest health plans, as well as leading health systems and innovative care management companies to serve diverse populations across all 50 states. Visit berrystreet.co to learn more. SOURCE Abbott For further information: Abbott Media: Monica Ma, [email protected], Abbott Financial: Michael Comilla, [email protected], Berry Street Media: Richard Fu, [email protected]
California joins $385 million Abbott settlement over infant formula claims. California Attorney General Rob Bonta announced on Sep. 21 that California, along with 39 other states and the federal government, has reached a $385 million settlement with Abbott Laboratories to resolve allegations related to the manufacture of certain powder infant formula and nutritional therapy products. Under the agreement, Abbott will pay $348.7 million to the United States for False Claims Act allegations and $35.5 million to participating states for Medicaid-related claims. California is set to receive over $15 million in restitution and other recoveries. "Today's settlement holds Abbott accountable for its misrepresentation of its product and production," said Bonta. "These state and federal regulations are in place to ensure we can provide the highest quality of care and products to mothers and their young children. This settlement sends the necessary message that these regulations aren't suggestions. My office is committed to ensuring all products we provide for Californians are truly as high quality as they claim to be." The U.S. Department of Agriculture funds and regulates the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC), which supplies nutritional support including infant formula; more than half of all infant formula purchased nationally is paid for through WIC funds. Many state Medicaid programs also cover specific powder infant formulas. The settlement resolves allegations that between 2018 and 2022, Abbott caused false claims by failing to comply with statutory, regulatory, and contractual requirements during manufacturing processes - allegedly putting products at risk of microorganism contamination affecting reliability, quality, and safety when purchased with taxpayer dollars. The resolved claims remain allegations only; there has been no determination of liability against Abbott Laboratories. Rob Bonta leads the California Attorney General's office, which serves as the state's chief law enforcement authority across California by enforcing laws related to civil rights, consumer protection, environmental justice, public safety initiatives, transparency tools such as the OpenJustice data portal, and policy advancement in economic security issues - all as part of its constitutional role within California's executive branch, according to the official website.